ConductScience.org, home

Paper35213635

Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach.

Beig Parikhani A and 10 others. PLoS One, 2022. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach. Papers, record 35213635. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35213635

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Human IL-2Rɑ subunit binding modulation of IL-2 through a decline in electrostatic interactions: A computational and experimental approach.
PubMed
Journal
PLoS One
PubMed
Year
2022
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
1.17
iCite
Revised in PubMed
2022-03-08
PubMed

Authors11

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Beig Parikhani AArezoo
2Bagherzadeh KKowsar
3Dehghan RRada
4Biglari AAlireza
5Shokrgozar MAMohammad Alihttps://orcid.org/0000-0002-9198-4070
6Riazi Rad FFarhad
7Zeinali SSirous
8Talebkhan YYeganeh
9Ajdary SSoheilahttps://orcid.org/0000-0002-5052-2523
10Ahangari Cohan RRezahttps://orcid.org/0000-0002-0490-4184
11Behdani MMahdihttps://orcid.org/0000-0002-4839-5123

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Interleukin-2 Receptor alpha SubunitMajor topic
Leukocytes, MononuclearMajor topic
Molecular Docking SimulationMajor topic
Molecular Dynamics SimulationMajor topic
Static ElectricityMajor topic
Humans
Interleukin-2
Protein Binding

Source PubMed

Download CSV of topics

References26

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123677467Human IL-2 mutein with higher antitumor efficacy than wild type IL-2.J Immunol2013https://conductscience.org/library/papers/23677467PubMed
227650575Selective targeting of IL-2 to NKG2D bearing cells for improved immunotherapy.Nat Commun2016https://conductscience.org/library/papers/27650575PubMed
331462678A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control.Nat Commun2019https://conductscience.org/library/papers/31462678PubMed
427697858IL2 Variant Circumvents ICOS+ Regulatory T-cell Expansion and Promotes NK Cell Activation.Cancer Immunol Res2016https://conductscience.org/library/papers/27697858PubMed
51282065
Treatment of BCL-1 murine B-cell leukemia with recombinant cytokines. Comparative analysis of the anti-leukemic potential of interleukin 1 beta (IL-1 beta), interleukin 2 (IL-2), interleukin-6 (IL-6), tumor necrosis factor alpha (TNF alpha), granulocyte colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), and their combination.
Leuk Lymphoma1992https://conductscience.org/library/papers/1282065PubMed
626572555Interleukin-2: Biology, Design and Application.Trends Immunol2015https://conductscience.org/library/papers/26572555PubMed
729854806Prospects of IL-2 in Cancer Immunotherapy.Biomed Res Int2018https://conductscience.org/library/papers/29854806PubMed
823611462Molecular dynamics simulation by GROMACS using GUI plugin for PyMOL.J Chem Inf Model2013https://conductscience.org/library/papers/23611462PubMed
923352221Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy.Immunity2013https://conductscience.org/library/papers/23352221PubMed
1016505437Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma.J Clin Oncol2006https://conductscience.org/library/papers/16505437PubMed
1124907378IL-2: the first effective immunotherapy for human cancer.J Immunol2014https://conductscience.org/library/papers/24907378PubMed
1218996896PDBsum new things.Nucleic Acids Res2009https://conductscience.org/library/papers/18996896PubMed
1323818175Motional timescale predictions by molecular dynamics simulations: case study using proline and hydroxyproline sidechain dynamics.Proteins2014https://conductscience.org/library/papers/23818175PubMed
148744570VMD: visual molecular dynamics.J Mol Graph1996https://conductscience.org/library/papers/8744570PubMed
159670041CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production.J Exp Med1998https://conductscience.org/library/papers/9670041PubMed
1624410537Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy.Expert Rev Clin Immunol2014https://conductscience.org/library/papers/24410537PubMed
1720547866Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells.Proc Natl Acad Sci U S A2010https://conductscience.org/library/papers/20547866PubMed
189504803SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling.Electrophoresis1997https://conductscience.org/library/papers/9504803PubMed
1923407358GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit.Bioinformatics2013https://conductscience.org/library/papers/23407358PubMed
207842289Induction of lymphokine-activated killing with reduced secretion of interleukin-1 beta, tumor necrosis factor-alpha, and interferon-gamma by interleukin-2 analogs.Ann Surg Oncol1994https://conductscience.org/library/papers/7842289PubMed

See all 26 referencesDownload CSV of references

Cited by7

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
40201389Cytokine Couture: Designer IL2 Molecules for the Treatment of Disease.Immunotargets Ther2025https://conductscience.org/library/papers/40201389PubMed
39425027Hypothetical proteins of chicken-isolated Limosilactobacillus reuteri subjected to in silico analyses induce IL-2 and IL-10.Genes Nutr2024https://conductscience.org/library/papers/39425027PubMed
38482625Specific Targeting of Zinc Transporter LIV-1 with Immunocytokine Containing Anti-LIV-1 VHH and Human IL-2 and Evaluation of its In vitro Antitumor Activity.Curr Pharm Des2024https://conductscience.org/library/papers/38482625PubMed
38337114A novel nanobody-based immunocytokine of a mutant interleukin-2 as a potential cancer therapeutic.AMB Express2024https://conductscience.org/library/papers/38337114PubMed
37430135
Comparison of the effects of probiotic strains (Lactobacillus gasseri, Lactiplantibacillus plantarum, Lactobacillus acidophilus, and Limosilactobacillus fermentum) isolated from human and food products on the immune response of CT26 tumor-bearing mice.
Braz J Microbiol2023https://conductscience.org/library/papers/37430135PubMed
36873499The protection quest is a primary key to sharing the neutralizing antibody response to cover against all emerging VOCs based on BIV1-CovIran studies.Heliyon2023https://conductscience.org/library/papers/36873499PubMed
35354847Efficacy and antitumor activity of a mutant type of interleukin 2.Sci Rep2022https://conductscience.org/library/papers/35354847PubMed

Download CSV of cited by

Genes9

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35213635

GET https://conductscience.org/api/papers/v1/35213635/references?page=2